All In MedTech

Device Trial Radar · NCT01876706

UroLift System TOlerability and ReCovery When Administering Local Anesthesia

L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia

Last checked: Nov 19, 2026Latest source record: Mar 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

51

Actual

Start

Apr 2013

Primary completion

Oct 2014

Study completion Sep 4, 2018

Sponsor

Lead sponsor
NeoTract, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 13, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate procedure tolerability and surgical recovery following the UroLift® system procedure when conducted with local anesthesia in subjects with symptomatic benign hyperplasia (BPH). Primary effectiveness will be achieved by looking at the Quality of Recovery Visual Analog Scale (QoR VAS) by the one month follow-up visit.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • UroLift® SystemDevice

    The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quality of RecoveryTime frame: 1 Month

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Genesis Research LLC

    San Diego, California

  • Advanced Urology Institute

    Daytona Beach, Florida

  • Pinellas Urology

    St. Petersburg, Florida

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.